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Candida infections represent a relevant 
risk for patients in intensive care units 
(ICU; [1, 2]) resulting in increased mor-
tality [3, 4, 5]. Adequate antifungal treat-
ment is essential in patients with sepsis to 
prevent irreversible damage due to micro-
bial load, systemic inflammation and or-
gan failure [6].
The echinocandins are large (molecu-
lar weight ~1200 kDa) semisynthetic cy-
clic hexapeptides derived from various 
natural fungal products [7, 8]. The lipo-
philic side chain of the echinocandins in-
tercalates with the phospholipid bilayer of 
the fungal cell membrane where it serves 
as a non-competitive inhibitor of β-1,3-D-
glucan synthase. Deficiency of β-1,3-D-
glucan in the fungal cell wall results in os-
motic instability and fungal cell lysis. The 
echinocandins have become the antifun-
gal agents of first choice due to the excel-
lent activity against most Candida strains 
and the favorable safety profile. Guide-
lines recommend echinocandins as pri-
mary therapy for all forms of candidiasis, 
especially in severely ill patients with or-
gan dysfunction [9, 10]. Development of 
septic cardiomyopathy reflects a crucial 
pathogenic part of hemodynamic instabil-
ity in septic shock which aggravates tissue 
hypoperfusion and organ failure [11]. Due 
to cardiac effects following echinocandin 
administration seen in ICU patients [12] 
the in vitro effects of echinocandins and 
fluconazole in clinically relevant concen-




Stock solutions of the three echinocan-
dins anidulafungin (Ecalta®, Pfizer, Ill-
ertissen, Germany), micafungin (Myca-
mine®, Astellas Pharma Europe, Leiden, 
The Netherlands) and caspofungin (Can-
cidas®, Merck Sharp & Dohme, Hertford-
shire, UK) as well as fluconazole (Diflu-
can®, Pfizer) were made by reconstitution 
of licensed preparations according to the 
product information. These were diluted 
directly before use with distilled water and 
10 µl of this dilution was added to 1 ml cul-
ture medium resulting in concentrations 
of 0.1–100 µg/ml. Control cultures were 
treated with distilled water only.
Isolation of cardiomyocytes
Animal experiments (sacrificing animals 
and organ extraction) were performed 
with approval by the animal welfare offi-
cer of the Faculty of Medicine of the Jus-
tus-Liebig University Giessen and in ac-
cordance with Federation of European 
Laboratory Animal Science Associations 
(FELASA) guidelines. Ventricular heart 
muscle cells were isolated from Lewis rats 
in a standard procedure as described in 
greater detail previously [13, 14]. Briefly, 
hearts from Lewis rats (age 3–4 months) 
were excised under deep ether anesthesia 
and mounted on the cannula of a Langen-
dorff perfusion system. Cardiomyocytes 
were isolated via perfusion with collage-
nase, followed by mincing, filtering and 
transfer to culture medium M199 supple-
mented with carnitine (2 mM), creatine 
(5 mM) and taurine (5 mM).
Incubation
A time-effect curve was constructed to 
investigate the representative duration for 
echinocandin incubation. Cardiomyo-
cytes were incubated with 10 μg/ml caspo-
fungin for 15 min, 90 min and 4 h, respec-
tively. Subsequently, experiments were 
performed after cardiomyocytes were cul-
tured in the presence of all licensed echi-
nocandin preparations at concentrations 
of 0 (control), 0.1, 1, 3.3, 10, 33, and 100 μg/
ml for 90 min. For fluconazole experi-
ments concentrations of 0 (control), 0.1, 1, 
3.3, 10, 20, and 100 μg/ml were used. Due 
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to the fact that fluconazole is supplied in 
a ready to use preparation (2 mg/ml), the 
highest achievable concentration in the 
experimental setup was 20 µg/ml. There-
fore, 100 µg/ml was achieved by adding 
five times the volume (=50 µl) compared 
to echinocandin preparations. To mimic 
plasma conditions two different methods 
of albumin incubation were used: the first 
series was performed by adding echino-
candin preparations in culture medium 
containing 10 mg/ml albumin for 15 min 
followed by replacing the original culture 
medium by the culture medium-albumin-
echinocandin mix and incubating the cells 
again for 90 min. An albumin concentra-
tion of 10 mg/ml was experimentally de-
termined as the highest concentration 
not affecting cardiomyocyte viability and 
contractility. The second series was per-
formed by applying echinocandin prep-
arations in culture medium containing 
10 mg/ml albumin that has already been 
in the culture dish. Each experiment was 
performed in duplicate and in a blinded 
manner.
Contractility measurements
Cell contraction was investigated using 
a cell edge detection system as described 
previously [15]. Briefly, cells were stimu-
lated by biphasic 50 V electrical stimu-
li of 0.5 ms duration via field stimulation 
by AgCl electrodes. Each cell was stimu-
lated at 2 Hz for 1 min. Cell contraction 
was measured at 5 intervals of 15 s and the 
mean of these 4 measurements was used 
to define the contractile responsiveness of 
a given cell. Cell lengths were measured at 
a rate of 500 Hz via a line camera. Data are 
expressed as ΔL/L (%) in which the short-
ening amplitude (ΔL) is expressed as a 
percentage of the diastolic cell length (L). 
At least 37 randomly selected cells from 
2 independent cardiomyocyte isolations 
were analyzed for each concentration and 
substance.
Rod-shaped:round cell ratio
Photographs of cultured cardiomyocytes 
were taken with a BZ-800K microscope 
(Keyence, Neu-Isenburg, Germany). 
From each culture dish five photographs 
from separate sections were taken and 
the rod-shaped:round cell ratio was de-
termined. On average approximately 400 
cells were analyzed per condition from 6 
culture dishes out of 2 preparations. Data 
were analyzed in a blinded manner.
Statistical analysis
Results are expressed as mean ± standard 
deviation. Differences between groups 
were analyzed globally by one-way ANO-
VA, followed by Dunnet’s post-test to 
compare different treatment groups to 
controls. A value of p<0.05 was regarded 
as significant. All analyses were done us-
ing GraphPad Prism version 5.04 for Mac 
(GraphPad Software, San Diego CA).
Results
In the experiments anidulafungin con-
centrations of 3.3, and 10 μg/ml showed 
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a b c d
Fig. 1 8 Effect of different antifungal preparations and concentrations on cellular parameters of isolated rat cardiomyocytes. 
a Contractility responsiveness measured as shortening ratio (dL/L). Graphs show mean values ± standard deviation. b Single 
cell observation of contractility at 3.3 and 10 µg/ml versus controls. c Rounded cells (grey bars) and rod-shaped cells (white 
bars) were counted. d Representive micrograph of culture dish following high-dose echinocandins given in culture medium 
containing 10 mg/ml albumin. Middle picture: overview, top and bottom: magnified areas of overview picture. Black line de-
picts limits of impact area
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sponsiveness in contrast to 0.1 and 1 μg/
ml which were not different compared to 
controls (. Fig. 1a,b; . Tab. 1). For ca-
spofungin cell shortening was not differ-
ent compared to controls for 0.1–3.3 μg/
ml; however, incubation with 10 μg/ml 
showed a significant decrease. Micafungin 
concentrations of 0.1 and 1 μg/ml showed 
no effect in contrast to controls while in-
cubation with 3.3–33 μg/m led to a sig-
nificant increase in cell shortening. Mea-
surement was not possible at 33 μg/ml for 
anidulafungin and caspofungin and at 
100 μg/ml for all echinocandins due to a 
majority of round-shaped, non-contract-
ing cardiomyocytes. Fluconazole showed 
no significant effect on cell shortening in 
all analyzed concentrations.
For all echinocandins the ratio of 
round-shaped, non-contracting versus 
rod-shaped normal-contracting cardio-
myocytes increased dose-dependently. A 
stable rate of 44.3–53.5% round-shaped 
cardiomyocytes was observed for anidu-
lafungin concentrations from 0.1 to 10 μg/
ml, whereas 86.6% and 99.8% of cardio-
myocytes were round-shaped at 33 μg/
Abstract · Zusammenfassung
Anaesthesist 2014 · 63:129–134  DOI 10.1007/s00101-014-2289-8
© The Author(s) 2014. This article is published with open access at Springerlink.com
C. Arens · F. Uhle · M. Wolff · R. Röhrig · C. Koch · A. Schulte · S. Weiterer · M. Henrich · M.A. Weigand · K.-D. Schlüter · C. Lichtenstern
Effects of echinocandin preparations on adult rat ventricular cardiomyocytes.  
Preliminary results of an in vitro study
Abstract
Background. Candida infections represent 
a relevant risk for patients in intensive care 
units resulting in increased mortality. Echino-
candins have become the agents of choice 
for early and specific antifungal treatment in 
critically ill patients. Due to cardiac effects fol-
lowing echinocandin administration seen in 
intensive care unit (ICU) patients the in vitro 
effects of echinocandins and fluconazole on 
isolated cardiomyocytes of the rat were ex-
amined.
Aim. The study was designed to investigate 
a possible impact of echinocandins and flu-
conazole in clinically relevant concentrations 
on the in vitro contractile responsiveness and 
shape of isolated rat cardiomyocytes.
Material and methods. Ventricular cardio-
myocytes were isolated from Lewis rats. Car-
diomyocytes were cultured in the presence 
of all licensed echinocandin preparations and 
fluconazol at concentrations of 0 (control), 
0.1, 1, 3.3, 10, 33 and 100 μg/ml for 90 min. 
Cells were stimulated by biphasic electrical 
stimuli and contractile responsiveness was 
measured as shortening amplitude. Addi-
tionally, the ratio of rod-shaped to round cells 
was determined.
Results. Anidulafungin concentrations of 3.3 
and 10 μg/ml caused a significant increase 
in contractile responsiveness, caspofungin 
showed a significant decrease at 10 μg/ml 
and micafungin concentrations of 3.3–33 μg/
ml led to a significant increase in cell shorten-
ing. Measurement was not possible at 33 μg/
ml for anidulafungin and caspofungin and at 
100 μg/ml for all echinocandins due to a ma-
jority of round-shaped, non-contracting car-
diomyocytes. Fluconazole showed no signif-
icant effect on cell shortening at all concen-
trations tested. For the three echinocandins 
the ratio of round-shaped, non-contracting 
versus rod-shaped normal contracting car-
diomyocytes increased in a dose-dependent 
manner.
Conclusions. Echinocandins impact the in 
vitro contractility of isolated cardiomyocytes 
of rats. This observation could be of great in-
terest in the context of antifungal treatment.
Keywords
Antifungal agents · Echinocandins · Adverse 
drug reaction · Cardiomyopathy · Organ 
failure
Wirkung von Echinocandinpräparaten bei adulten ventrikulären Kardiomyozyten.  
Erste Ergebnisse einer In-vitro-Studie
Zusammenfassung
Hintergrund. Candida-Infektionen stellen 
ein relevantes Risiko für Patienten einer In-
tensivstation dar und führen zu einer erhöh-
ten Mortalität. Echinocandine sind mittler-
weile Mittel der Wahl für die frühzeitige und 
spezifische antimykotische Behandlung kri-
tisch kranker Patienten. Aufgrund kardialer 
Wirkungen nach Echinocandingabe bei den 
Intensivpatienten der Autoren wurden die 
In-vitro-Wirkungen von Echinocandinen und 
Fluconazol auf isolierte Kardiomyozyten der 
Ratte untersucht.
Ziel der Arbeit. Die Studie wurde durchge-
führt, um den möglichen Einfluss von Echino-
candinen und Fluconazol in klinisch relevan-
ten Konzentrationen auf die In-vitro-Kontrak-
tilität und die Form isolierter Rattenkardio-
myozyten zu bestimmen.
Material und Methoden. Ventrikuläre Kar-
diomyozyten wurden aus Lewis-Ratten iso-
liert. Die Kardiomyozyten wurden mit sämtli-
chen zugelassenen Echinocandinpräparaten 
und Fluconazol in den Konzentrationen von 
0 (Kontrolle); 0,1; 3,3; 10; 33 und 100 μg/
ml über 90 min kultiviert. Mit biphasischen 
elektrischen Reizen erfolgte die Stimulation 
der Zellen, und die Kontraktilität wurde als 
Verkürzung der Amplitude gemessen. Außer-
dem wurde das Verhältnis stäbchenförmiger 
Zellen zu runden Zellen ermittelt.
Ergebnisse. Eine Anidulafunginkonzentra-
tion von 3,3 sowie von 10 μg/ml verursachte 
einen signifikanten Anstieg der Kontraktili-
tät; bei Caspofungin zeigte sich eine signifi-
kante Verminderung bei 10 μg/ml; und Mi-
cafunginkonzentrationen von 3,3–33 μg/ml 
führten zu einem signifikanten Anstieg der 
Zellverkürzung. Aufgrund einer Mehrzahl 
von runden, nichtkontraktilen Kardiomyozy-
ten war die Messung bei einer Konzentration 
von 33 μg/ml Anidulafungin und Caspofun-
gin sowie für alle Echinocandine bei 100 μg/
ml nicht möglich. Bei Fluconazol fand sich in 
allen analysierten Konzentrationen keine sig-
nifikante Wirkung auf die Zellverkürzung. Bei 
den 3 Echinocandinen stieg das Verhältnis 
runder, nichtkontraktiler Zellen gegenüber 
den stäbchenförmigen, normalkontraktilen 
Kardiomyozyten dosisabhängig an.
Schlussfolgerung. Echinocandine beeinflus-
sen die In-vitro-Kontraktilität isolierter Kar-
diomyozyten von Ratten. Diese Beobachtung 
könnte im Rahmen einer antimykotischen 
Behandlung von hohem Interesse sein.
Schlüsselwörter
Antimykotika · Echinocandine · 
Nebenwirkung · Kardiomyopathie · 
Organversagen
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ml and 100 μg/ml, respectively (. Fig. 1c; 
. Tab. 2). Caspofungin concentrations 
of 0.1 and 1 μg/ml provided compara-
ble proportions of rounded cardiomyo-
cytes as controls while the proportion in-
creased dose-dependently from 3.3 µg/ml 
to 100 µg/ml from 63.6% to 73.1%, 97.2% 
and 100%, respectively. At micafungin 
concentrations of 0.1–10 μg/ml equiva-
lent fractions of round-shaped cardiomy-
ocytes were seen as in controls; however, 
at concentrations of 33 and 100 μg/ml car-
diomyocytes revealed a rounded shape in 
66.4 and 95.3%, respectively. Fluconazole 
showed no significant effect on shape at all 
analyzed concentrations.
The rate of round-shaped cardiomy-
ocytes, following high-dose echinocan-
dins given in culture medium containing 
10 mg/ml albumin, proceeded accord-
ing to assumed concentration gradients 
(. Fig. 1d). Preincubation of echinocan-
dins with 10 mg/ml albumin led to cancel-
lation of all of the described effects.
Discussion
The results revealed for the first time that 
echinocandin preparations in contrast to 
fluconazole have a dose-dependent im-
pact on function and shape of isolated 
rat cardiomyocytes in vitro. Neverthe-
less, there has already been evidence of an 
ex vivo cardiotoxicity in rats performed 
with a Langendorff heart experiment 
[16]. Some very recent clinical reports de-
scribed severe hemodynamic instability 
during anidulafungin administration in a 
critically ill ICU patient [17] and a flash 
pulmonary edema of unknown origin in 
a 52-year-old male [18]. Cardiac effects 
following echinocandin administration 
have also been seen in septic ICU patients 
[12]. Additionally, Stover et al. [16] sum-
marized four cases from the FDA adverse 
events reporting system (FAERS) which 
may reflect the cardiac impact of the echi-
nocandins: two reports of arrhythmia (an-
idulafungin), one cardiac failure (anidula-
fungin) and one described as sudden car-
diac death (caspofungin; [19]).
Regarding effective tissue concentra-
tions, there are some limits in transfer-
ring the effects of isolated cardiomyo-
cytes to an in vivo situation. Cardiomy-
ocytes are protected in vivo by an endo-
thelial barrier; however, disrupted endo-
thelial layers in sepsis might promote in-
creased antifungal tissue concentrations. 
Consequently trough concentrations of 
caspofungin in critically ill patients were 
found to be higher (mean 2.16 µg/ml) 
than in healthy subjects [20]. Addition-
ally, even in healthy patients caspofungin 
already reaches peak plasma concentra-
tions up to 20 µg/ml [21] and 9.94 µg/ml 
in steady state, while heart tissue reaches 
about 50% of plasma concentrations [22, 
23] anidulafungin reaches maximum lev-
els up to 14 µg/ml [24, 25] and the peak 
micafungin plasma concentration is ap-
proximately 8.8 µg/ml [26]. Recommend-
ed dose regimens provide loading dosages 
for caspofungin and anidulafungin which 
could lead to even higher intramyocardial 
concentrations. Regarding this, all clinical 
echinocandin effects which were reported 
in the case reports [12, 17] were seen ac-
cording to initial loading dosages (200 mg 
anidulafungin and 70 mg caspofungin) in 
critically ill septic patients.
Because echinocandins are highly pro-
tein-bound in plasma and thus the total 
concentration could be many times higher 
than the free concentration, albumin was 
added to mimic plasma conditions. Pri-
marily, it has to be considered that serum 
albumin levels are frequently decreased 
in patients at risk for invasive fungal in-
fections which would increase the active 
drug concentration. Additionally, no data 
concerning the kinetics of protein bind-
ing of echinocandins following bolus infu-
sion in humans appear to have been pub-
lished. Especially in situations when anti-
fungal treatment is needed, it is mostly ad-
ministered through a central line, which 
could be followed by high active cardiac 
concentrations due to less time to bind to 
proteins. Moreover, standard minimum 
inhibitory concentrations (MIC) of echi-
nocandins used to predict treatment re-
sponse are estimated in the absence of al-
bumin. However, albumin addition to this 
microbiological testing significantly raises 
the MIC to values above the cut-off that 
is applied to classify microbiological re-
Tab. 1 Values of mean contractility (mean dL/L), standard deviation (SD), number of cells (N) 




0.1 1 3.3 10 33 100
Anidu-
lafungin
Mean dL/L 7.899 8.096 8.970 9.479 9.627   
SD 2.101 1.964 2.164 2.646 2.800   
N 54 54 44 54 37   
Significance vs. 
control
ns ns ns ** **   
Caspo-
fungin
Mean dL/L 8.053 8.359 7.951 7.095 4.834   
SD 1.923 2.372 2.191 1.944 2.079   
N 54 54 54 54 54   
Significance vs. 
control
ns ns ns ns ***   
Mica-
fungin
Mean dL/L 8.033 7.791 7.796 9.436 10.01 10.71  
SD 2.333 1.775 2.024 2.350 3.156 3.196  
N 54 54 54 54 53 54  
Significance vs. 
control
ns ns ns * *** ***  
Flucon-
azole
Mean dL/L 10.14 10.55 10.28 9.784 9.518 9.957 9.670
SD 2.636 1.990 2.588 2.709 2.585 2.379 2.978
N 54 54 54 54 54 54 54
Significance vs. 
control
ns ns ns ns ns ns ns
Blank cells are depicted where no measurements were possible, italics indicate differential treatment regard-
ing fluconazole concentration (33=20 µg/ml and 100 µg/ml concentration was achieved by adding five times 
the volume of solution than other treatments) ns not significant*p≤0.05, **p≤0.001, ***p≤0.0001
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sistance. Data from phase 2 and 3 stud-
ies have not described adverse events re-
garding cardiac failure following echino-
candin administration. Product informa-
tion for caspofungin from the European 
Medicines Agency (EMA) mentions oc-
casional congestive heart failure. Howev-
er, most studies on antifungal agents did 
not include a relevant rate of critically ill 
patients and therefore, hemodynamic re-
serves might have been sufficient in the 
overall study populations. In contrast in 
septic patients it is possible that a drug-re-
lated cardiac failure is wrongly attributed 
to a progress of illness. According to the 
drug evaluation documents from EMA 
and the U.S. Food and Drug Administra-
tion (FDA), hypotension and a hemody-
namic breakdown are described for an ex-
perimental administration of caspofungin 
in rats. This was associated with vascular 
histamine release. It has not yet been ex-
amined if histamine release is a possible 
mechanism of the observed effects. Nev-
ertheless, the very recent report from Fink 
et al. [17] and in vivo observations in three 
patients [12] lead to the assumption that 
there must be an additional non-hista-
mine-related pathway which leads to car-
diac breakdown. Additionally histamine-
releasing cells (e.g. mast cells) as media-
tors were not observed in the preparations 
in the current study.
The results of the study do not give the 
explanation for the mechanism of the ob-
served effects on isolated cardiomyocytes 
by echinocandins. As Stover et al. [16] 
based on other publications [27, 28] al-
ready mentioned, there are several possi-
ble mechanisms of drug-induced cardio-
myopathy. The evidence of myocyte and 
mitochondrial damage was observed us-
ing transmission electron microscopy 
[16]. Furthermore, the observed round-
ed shape of isolated cardiomyocytes in 
the current experiments indicates a dis-
turbed intracellular calcium homeosta-
sis. However, the possibility of a recep-
tor mediated mechanism or direct tox-
ic effects, e.g. due to oxidative stress can-
not be ruled out. Because of the rapidity 
in which the effects appeared, alterations 
in cardiomyocyte gene expression or pro-
tein synthesis are not very likely to be the 
reason for the observed effect. Because of 
the absence of endothelial cells in the ex-
perimental set-up any involvement of en-
dothelial cells in the observed results can 
be ruled out. Remarkably, lower doses of 
anidulafungin (3.3 and 10 µg/ml) and mi-
cafungin (3.3, 10 and 33 µg/ml) caused an 
increase in contractility responsiveness 
whereas caspofungin (10 µg/ml) led to a 
decrease. However, the same rounded fib-
rillating shape of the isolated cardiomyo-
cytes without a straightened contraction 
was observed when exposed to high doses 
of all echinocandins. Although the molec-
ular structure of the scaffold is very sim-
ilar, the echinocandins have some differ-
ences in the side chains what is assumed 
to be the reason for such differences [25]. 
This might also be the reason why the 
MICs of the echinocandins are not equal 
[8, 29, 30]. Nevertheless, the rate of car-
diomyocytes with a round cell shape con-
sistently increases for all echinocandins 
dose-dependently.
There are some limitations of the 
study: First of all, the results from isolat-
ed rat cardiomyocytes are not transferable 
one-to-one to the human clinical setup 
on the ICU. Isolated cells are not protect-
ed by endothelium and higher free echi-
nocandin expositions are even implicated 
by the absence of albumin in the exper-
iment. Additionally, clinical case reports 
described effects in septic critically ill pa-
tients whereas the experiments were per-
formed in cells harvested from healthy an-
imals. Due to the experimental approach, 
it is not possible to give decisive recom-
mendations for the clinical choice of any 
echinocandin preparation or a required 
modification of the way of administra-
tion. Finally, it is not clear whether the 

















Prof. Dr. M.A. Weigand 
Department of Anesthesiology and Intensive 
Care Medicine, University Hospital of Gießen 
and Marburg, Campus Gießen
Rudolf-Buchheim-Str. 7,  
35392 Gießen, Germany
markus.weigand@chiru.med.uni-giessen.de
Tab. 2 Values of cell morphology (% rounded), standard deviation (SD) and number of cells 




0.1 1 3.3 10 33 100
Anidu-
lafungin
% Rounded 48.1 44.3 53.5 49.7 47.3 86.6 99.8
SD 13.0 12.0 12.0 7.0 9.0 9.0 1.0
N 496 443 498 481 557 591 612
Caspo-
fungin
% Rounded 49.7 44.1 54.0 63.6 73.1 97.2 100
SD 11.5 12.0 17.9 17.5 9.0 3.3 –
N 474 440 433 423 431 515 441
Mica-
fungin
% Rounded 45.4 47.5 50.9 49.5 44.1 66.4 95.3
SD 7.5 12.5 17.2 10.0 16.4 10.9 3.2
N 495 491 526 492 474 476 476
Flucon-
azole
% Rounded 51.7 53.3 51.9 48.1 56.1 55.2 49.4
SD 12.6 9.5 10.3 7.6 16.5 8.9 13.7
N 403 426 481 430 474 529 403
Figures in italics indicate differential treatment regarding fluconazole concentration (33=20 µg/ml and 100 µg/
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